Diabetes, obesity & metabolism · 2026
Real-world treatment trajectories preceding GLP-1 receptor agonist initiation in type 2 diabetes: A descriptive UK population-based cohort study on adherence to national clinical guidelines.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ulrich Franziska S, Frost Nielsen Morten, Napoli Nicola, Burden Andrea M
Аннотация
AIMS: To investigate glucose-lowering treatment trajectories preceding glucagon-like peptide-1 receptor agonist (GLP-1RA) initiation in UK primary care, while assessing alignment with contemporary UK clinical guidelines, considering calendar time, cardiovascular disease (CVD) history, and obesity status.
MATERIALS AND METHODS: Using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, a Cegedim Database, we included adults with type 2 diabetes initiating GLP-1RAs in UK primary care between 01 January 2007 and 30 June 2023. We described treatment trajectories from the first glucose-lowering therapy to GLP-1RA initiation, stratified by calendar time (GLP-1RA initiation pre- or post-01 January 2018, when guidelines started recommending sodium-glucose co-transporter-2 inhibitors [SGLT-2is] for those at high risk or established CVD), CVD history, and body mass index (BMI) ≥35 kg/m2.
RESULTS: We included 29 780 GLP-1RA initiators, with 62.2% (n = 18 517) initiating pre-2018 and 37.8% (n = 11 263) post-2018. Consistent over calendar time, most GLP-1RA initiators (63.5%) received their first GLP-1RA as fourth-line (35.4%) or later-line therapy (28.1%), with fewer initiating GLP-1RAs as first- (0.8%), second- (10.5%), or third-line (25.2%) treatments. After 2018, 50.8% of individuals initiating GLP-1RA therapy used SGLT-2is concomitantly, regardless of CVD status (47.8% with established CVD vs. 51.5% without). Individuals with BMI ≥35 kg/m2 initiated GLP-1RA therapy earlier compared to those with BMI <35 kg/m2 (46.3% vs. 29.1% as first-, second-, or third-line treatment).
CONCLUSIONS: GLP-1RAs were predominantly initiated following ≥3 glucose-lowering agents, consistent with contemporary UK guidance (NG28). Post-2018, most GLP-1RA initiators received SGLT-2is concomitantly. However, CVD history did not influence prescribing patterns, underscoring missed opportunities to optimise the prevention of cardiovascular events and slow the progression of CVD.
MATERIALS AND METHODS: Using the IQVIA Medical Research Data (IMRD) incorporating data from THIN, a Cegedim Database, we included adults with type 2 diabetes initiating GLP-1RAs in UK primary care between 01 January 2007 and 30 June 2023. We described treatment trajectories from the first glucose-lowering therapy to GLP-1RA initiation, stratified by calendar time (GLP-1RA initiation pre- or post-01 January 2018, when guidelines started recommending sodium-glucose co-transporter-2 inhibitors [SGLT-2is] for those at high risk or established CVD), CVD history, and body mass index (BMI) ≥35 kg/m2.
RESULTS: We included 29 780 GLP-1RA initiators, with 62.2% (n = 18 517) initiating pre-2018 and 37.8% (n = 11 263) post-2018. Consistent over calendar time, most GLP-1RA initiators (63.5%) received their first GLP-1RA as fourth-line (35.4%) or later-line therapy (28.1%), with fewer initiating GLP-1RAs as first- (0.8%), second- (10.5%), or third-line (25.2%) treatments. After 2018, 50.8% of individuals initiating GLP-1RA therapy used SGLT-2is concomitantly, regardless of CVD status (47.8% with established CVD vs. 51.5% without). Individuals with BMI ≥35 kg/m2 initiated GLP-1RA therapy earlier compared to those with BMI <35 kg/m2 (46.3% vs. 29.1% as first-, second-, or third-line treatment).
CONCLUSIONS: GLP-1RAs were predominantly initiated following ≥3 glucose-lowering agents, consistent with contemporary UK guidance (NG28). Post-2018, most GLP-1RA initiators received SGLT-2is concomitantly. However, CVD history did not influence prescribing patterns, underscoring missed opportunities to optimise the prevention of cardiovascular events and slow the progression of CVD.